Synthesis, Characterization, and Biological Study of 3‐Trifluoromethylpyrazole Tethered Chalcone‐Pyrrole and Pyrazoline‐Pyrrole Derivatives
Nishant K. Rasal, Rahul Sonawane, Sangeeta V. Jagtap
Abstract
Abstract The present study illustrates the design and synthesis of new series of 3‐trifluoromethylpyrazole tethered chalcone‐pyrrole and pyrazoline‐pyrrole derivatives. All compounds were further screened for in vitro cytostatic activities on full NCI 60 cancer cell lines at National Cancer Institute, USA. Compounds (2 E )‐3‐(1 H ‐pyrrol‐2‐yl)‐1‐{4‐[3‐(trifluoromethyl)‐1 H ‐pyrazol‐1‐yl]phenyl}prop‐2‐en‐1‐one ( 5a ) and (2 E )‐1‐{3‐methyl‐4‐[3‐(trifluoromethyl)‐1 H ‐pyrazol‐1‐yl]phenyl}‐3‐(1 H ‐pyrrol‐2‐yl)prop‐2‐en‐1‐one ( 5c ) displayed significant antiproliferative activity (Growth Percentage: −77.10 and −92.13, respectively at 10 μM concentration) against the UO‐31 cell lines from renal cancer and were further selected for assay at 10‐fold dilutions of five different concentrations (10 −4 to 10 −8 M). Both compounds 5a and 5c exhibited promising antiproliferative activity (GI 50 : 1.36 to 0.27 μM) against leukemia cancer cell lines HL‐60 and RPMI‐8226, colon cancer cell lines KM‐12; breast cancer cell lines BT‐549. Moreover, both compounds 5a and 5c were found to be non‐cytotoxic (LC 50 >100) against HL‐60, RPMI‐8226, and KM‐12 cell lines. Remarkably, GI 50 values of compounds 5a and 5c were identified as more promising than sunitinib against most cancer cell lines. In silico study of compounds 5a and 5c exemplified the desired ADME properties for drug‐likeness as well as tighter interactions with VEGFR‐2. Hence, compounds 5a and 5c would be good cytotoxic agents after further clinical study.